Target intelligence / Profile preview

Structural maintenance of chromosomes flexible hinge domain-containing protein 1 (SMCHD1)

Target
SMCHD1
Molecular classification
Non-canonical structural maintenance of chromosomes (SMC) protein, Chromatin regulator, Epigenetic modifier, ATPase, Other
01

Overview

Structural maintenance of chromosomes flexible hinge domain-containing protein 1 (SMCHD1) is a large, non-canonical SMC family protein involved in epigenetic gene silencing by regulating chromatin structure and DNA methylation[1][2][3][4][5]. SMCHD1 plays a critical role in processes such as X-chromosome inactivation and the repression of gene expression at specific loci including the D4Z4 repeat array and Hox clusters[2][4]. Mutations in SMCHD1 are causally linked with facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS), demonstrating an important role in muscular function and craniofacial development[1][2][3][4][5]. SMCHD1 contains a GHKL ATPase domain and a unique hinge domain responsible for DNA binding and dimerization, distinguishing it from canonical SMC proteins[1][3][4][6]. The protein’s mechanism involves recruiting chromatin-modifying machinery, promoting DNA methylation, and influencing 3D chromatin architecture[2][4]. Currently, no specific drugs directly target SMCHD1, but understanding its structure has enabled research into epigenetic therapies targeting diseases associated with its dysfunction[3][4].

Other names
SMC hinge domain-containing protein 1KIAA0650FSHD2BAMSSMCHD1structural maintenance of chromosomes flexible hinge domain containing 1
02

Biological functions

Epigenetic gene silencingChromatin modificationDNA methylationLong-range chromatin interactionsX-chromosome inactivationSilencing of specific genomic regions (e.g., D4Z4, Hox clusters)DNA repair (putative)
03

Disease associations

Facioscapulohumeral muscular dystrophy type 2 (FSHD2)Bosma arhinia microphthalmia syndrome (BAMS)Developmental disorders affecting craniofacial developmentOther
04

Safety considerations

Potential off-target effects due to broad role in gene silencing and chromatin architecture if therapeutically targetedUnintended consequences on development or cell identity in epigenetic therapy
05

Biomarkers

SMCHD1 gene mutations (for FSHD2 and BAMS diagnosis)DNA methylation status at D4Z4 (for FSHD2)

Beyond the preview

Go deeper on Structural maintenance of chromosomes flexible hinge domain-containing protein 1 (SMCHD1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Structural maintenance of chromosomes flexible hinge domain-containing protein 1 (SMCHD1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call